<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555982</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0245</org_study_id>
    <secondary_id>2015-000162-59</secondary_id>
    <nct_id>NCT02555982</nct_id>
  </id_info>
  <brief_title>Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor</brief_title>
  <acronym>Btx-HT</acronym>
  <official_title>Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Essential head tremor (HT) does not usually respond to drug treatment such as propranolol or
      primidone or to surgical treatment such as deep brain stimulation of the thalamic ventralis
      intermedius nucleus. Botulinum toxin (Btx) is widely used and efficient in the treatment of
      blepharospasm and cervical dystonia. Btx prevents the release of acetylcholine in synapses,
      leading to a reduction of pathological muscle movement. Very little information is available
      on its efficacy on HT. Two published reports suggested that local Btx A injections could be
      an effective and safe approach for treating HT. Given the scarcity of published data (small
      samples, open studies, different doses of Btx used, heterogeneous populations, several
      muscles injected, etc.), the aim of this study is to demonstrate the efficacy of Btx
      injections in essential HT by a multi-center, randomized, double-blind, parallel-group,
      placebo-controlled study.

      Principal objective: To evaluate the efficacy of botulinum toxin injections in the treatment
      of head tremor.

      Secondary objectives:

        -  - To evaluate the tolerance of botulinum toxin injections in the treatment of head
           tremor.

        -  - To evaluate the impact of botulinum toxin injections on the patients' quality of life
           and embarrassment.

        -  To evaluate the changes of tremor characteristics induced by a Btx treatment using a 3D
           accelerometer wireless portable system (Xsens MTw wireless motion tracker system)
           (tremor frequency, tremor displacement, mean peak amplitude, distance traveled) and a
           new video system device to analyze head tremor characteristics
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type of study: multi-center, randomized, double-blind, parallel-group, placebo-controlled
      therapeutic clinical trial.

      Number of centers: 13 centers : Clermont-Ferrand, Paris (Fondation Rothschild et APHP),
      Toulouse, Lyon, Amiens, Bordeaux, Narbonne, Lille, Strasbourg, Nîmes, Marseille, Besançon.

      Medical product Botulinum toxin type A, 200U (BOTOX ® 200 Unités, Allergan)

      Patients

      Patients eligible for inclusion will be randomized to one of the two groups:

        -  Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan),
           one on D0 and one at 12W (into each splenius capitis).

        -  Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at
           12W (into each splenius capitis).

      Study Performance Patients will be injected twice, with an interval of 12 weeks (D0 and 12W).
      On D0, patients will receive 75U of Btx A (BOTOX ® - Allergan) in each splenius capitis; at
      12W, patients will receive the same dose as on D0 (if the first injection is effective
      according to the CGI- improvement by at least two points), or a higher dose (100U) (if the
      first injection is ineffective according to the CGI- non improvement or improvement by less
      than two points).

      Patients will be assessed at baseline D0, 6 weeks (6W), 12 weeks (12W), 18 weeks (18W) and 24
      weeks (24W) after D0 as follows:

      Visit 1 (baseline):

        -  Signature of an informed consent form.

        -  Demographic and clinical characteristics (sex, age, disease duration, treatments).

        -  Clinical evaluation:

        -  Neurological evaluation: Fahn-Tolosa-Marin Tremor Rating Scale (TRS), Tsui Scale.

        -  The Quality of life in Essential Tremor (QUEST), the Essential Tremor Embarrassment
           Assessment (ETEA).

        -  Accelerometer recording and videotape recording.

      Visits at 6W, 12W, 18W and 24W

        -  Clinical evaluation:

        -  TRS.

        -  CGI.

        -  QUEST / ETEA.

        -  Accelerometer recording and videotape recording.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical state improvement of patients evaluated by the Clinical Global Impression of Change (CGI)</measure>
    <time_frame>at 18 weeks</time_frame>
    <description>clinical state improvement of patients evaluated by the Clinical Global Impression of Change (CGI) (improvement by at least two points) measured 6 weeks after the 2nd injection of Btx (at 18W).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of responders defined with CGI</measure>
    <time_frame>at 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>% of responders defined with CGI</measure>
    <time_frame>at 18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (sub item head)</measure>
    <time_frame>at day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (sub item head)</measure>
    <time_frame>at 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (sub item head)</measure>
    <time_frame>at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (sub item head)</measure>
    <time_frame>at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (sub item head)</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Essential Tremor Embarrassment Assessment (ETEA)</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Essential Tremor Embarrassment Assessment (ETEA)</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Essential Tremor Embarrassment Assessment (ETEA)</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Essential Tremor Embarrassment Assessment (ETEA)</measure>
    <time_frame>at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Essential Tremor Embarrassment Assessment (ETEA)</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of life in Essential Tremor (QUEST)</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of life in Essential Tremor (QUEST)</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of life in Essential Tremor (QUEST)</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of life in Essential Tremor (QUEST)</measure>
    <time_frame>at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of life in Essential Tremor (QUEST)</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tremor frequency measured by accelerometer</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tremor frequency measured by accelerometer</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tremor frequency measured by accelerometer</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tremor frequency measured by accelerometer</measure>
    <time_frame>at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tremor frequency measured by accelerometer</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean peak amplitude measured by accelerometer</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean peak amplitude measured by accelerometer</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean peak amplitude measured by accelerometer</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean peak amplitude measured by accelerometer</measure>
    <time_frame>at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean peak amplitude measured by accelerometer</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance traveled measured by accelerometer</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance traveled measured by accelerometer</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance traveled measured by accelerometer</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance traveled measured by accelerometer</measure>
    <time_frame>at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance traveled measured by accelerometer</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Essential Head Tremor</condition>
  <arm_group>
    <arm_group_label>EXPERIMENTAL GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients eligible for inclusion will be randomized to one of the two groups:
Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients eligible for inclusion will be randomized to one of the two groups:
Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX ® 200 Unités</intervention_name>
    <description>Patients eligible for inclusion will be randomized to one of the two groups:
Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).</description>
    <arm_group_label>EXPERIMENTAL GROUP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).</description>
    <arm_group_label>CONTROL GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from a head tremor without (isolated) or with associated

          -  tremor in any other body parts.

          -  The HT must be troublesome for the patients (TRS 2 for the head tremor

          -  severity item).

          -  Patients never treated with botulinum toxin or not treated with botulinum toxin for
             this indication for at least 4 months.

          -  Men or women aged from 18 to 80 years old.

          -  Social security coverage.

          -  Ability to provide informed consent.

        Exclusion Criteria:

          -  Patients with tremor from cerebellar syndrome (multiple sclerosis, etc.).

          -  Patients with a predominant dystonic jerky or myoclonic head tremor using

          -  the Tsui scale (&gt;1).

          -  Oral treatments for HT are allowed but must be stable during the study.

          -  Any contra-indication to Botulinum toxin.

          -  Women without efficient contraception.

          -  Patients under supervision or (legal) guardianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Durif</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>04 73 75 11 95</phone>
    <email>drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Pays D'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GAYRAUD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique GAYRAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélissa TIR</last_name>
    </contact>
    <investigator>
      <last_name>Mélissa TIR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent TATU</last_name>
    </contact>
    <investigator>
      <last_name>Laurent TATU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Levêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BURBAUD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre BURBAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Franck DURIF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital R Salendro</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre KREISLER</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre KREISLER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital neurologique</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe VIAL</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Vial</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique FLUCHERE</last_name>
    </contact>
    <investigator>
      <last_name>Frédérique FLUCHERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria GONZALEZ</last_name>
    </contact>
    <investigator>
      <last_name>Victoria GONZALEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Narbonne</name>
      <address>
        <city>Narbonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève FOURCADE BLANCHET</last_name>
    </contact>
    <investigator>
      <last_name>Geneviève FOURCADE BLANCHET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Caremeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni CASTELNOVO</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni CASTELNOVO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand DEGOS</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand DEGOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie SANGLA</last_name>
    </contact>
    <investigator>
      <last_name>Sophie SANGLA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH F. Mittérand</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno BARROSO</last_name>
    </contact>
    <investigator>
      <last_name>Bruno BARROSO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Benatru</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Benatru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine TRANCHANT</last_name>
    </contact>
    <investigator>
      <last_name>Christine TRANCHANT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion SIMONETTA-MOREAU</last_name>
    </contact>
    <investigator>
      <last_name>Marion SIMONETTA-MOREAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential Head tremor</keyword>
  <keyword>Botulinum toxin injections</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Embarrassment assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

